DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair,With death on the horizon, This will not stop me, Gods call only..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contributio
n

Saturday, 16 May 2015

Dr. Rina Chokshi




Rina Chokshi

Americas Application Manager, Health at FMC Corporation


- Expertise in design and development of solid dosage forms of BCS 2/4 compounds and challenging molecules; knowledgeable about biopharmaceutical challenges and regulatory requirements for BA/BE studies
- Experienced in development of conventional as well as novel dosage forms, including solid dispersions such as Hot-melt Extrusion/ Spray-drying/Co-precipitation as well as controlled release formulations
- Leadership roles in cross-functional global product development team with successful execution of formulation and process development strategies, scale-up, and manufacture of clinical, registration/validation batches 
- Extensive experience on formulation and process optimization at small scale using Quality by Design (QbD) approach and successful technology/ knowledge transfer to commercial facilities.

Specialties:Formulation/Process development, formulation/process optimization with Quality by Design, Process scale- up, formulation development of poorly water soluble drugs (solid dispersion and solid solution)

Dr. Rina Chokshi has over several years of experience in formulation and process development. Rina has worked on the development of conventional as well as novel dosage forms, including solid dispersions such as hot-melt extrusion, spray-drying and co-precipitation as well as controlled release formulations. 

She earned her Ph.D. from the University of Rhode Island in collaboration with Hoffman-La Roche, and went on to work for Wyeth (now Pfizer) on formulation and process optimization using Quality by Design (QbD) approaches

https://www.linkedin.com/in/rinachokshi

Rina Chokshi

Education




University of Mumbai

Bachelor, Pharmacy

Experience





Americas Application Manager, Health

FMC Corporation
 – Present Ewing, NJ




Project leader, Controlled release technology

FMC BioPolymer
 – Present (4 years 10 months)




Principal Research Scientist

Pfizer
 –  (11 months)




Principal Research Scientist

Wyeth Pharmaceuticals
 –  (2 years)
- Lead the team for formulation and process development and optimization using Quality by Design (QbD) approach
- Designed and executed formulation and process optimization studies at small scale and successful scale up to commercial manufacturing sites
- Developed formulation and process for bilayer tablets containing immediate release and controlled release granulations
- Successfully coordinated clinical manufacture supplies for phase 2 and phase 3
- Hands on experience in direct compression, roller compaction, fluid bed granulation, fluid bed coating, wet granulation, and hot melt extrusion technology platform




Senior Research Scientist I and II

Wyeth Research
 –  (3 years 7 months)
- Lead formulator for developing poorly water soluble drug formulations using various novel technologies
- Lead coordinator for technology transfer, manufacture of clinical batches and manufacture of registration batches and validation batches at commercial facilities
- Responsible for preparing Pharmaceutical development reports for regulatory submission and functioned as lead formulator responsible for drafting response for various agencies such as FDA and EMEA




Research Assitant

Hoffman-La Roche
 –  (5 years)
- Conducted M.S. and Ph.D. thesis research in an industrial setting
- Developed and evaluated solid dispersions and solid solutions of poorly water soluble compounds using various techniques such as Hot-melt extrusion, Spray drying, Co-precipitation and Co-evaporation
- Assisted in various Roche projects and contributed to the development of tablet and capsule dosage forms of poorly water soluble drugs

Evaluation of hot -melt extrusion technology to improve dissolution rates of poorly water soluble drugs. Rina Chokshi, University of Rhode Island ...
digitalcommons.uri.edu/dissertations/AAI3145415/
Chokshi, Rina and Hossein Zia. "Hit Melt Extrusion Technique: A Review." Journal .... May 2004. Zia, Hossein. SEE also: Chokshi, RIna. Zia, H. " Enhancement of ...
www.uri.edu/library/faculty_publications/2004/aps04.html
... THE ROAD MARKING LUMINANCE CONTRAST AND VARIABLE MESSAGE SIGNSRina Chokshi - PhD Applied Pharmaceutical Sciences - Thursday, May 6  ...
listserv.uri.edu/cgi-bin/wa?A2=ind0405&L...F=&S...
Chokshi, Rina J., Harpareet Sandhu, Raman M. Iyer, Navnit H. Shaw, A. Waseem Malick and Hossein Zia. "Characterization of Physico-Mechanical Properties of ...
www.uri.edu/library/faculty_publications/2005/bms05.html
Chokshi, Rina J., Hossein Zia, Harpreet K. Sandhu, Navnit H. Shah and Waseem A. Malick. "Improving the Dissolution Ration of Poorly Water Soluble Drug by ...
www.uri.edu/library/faculty_publications/2007/bms07.html
File Format: PDF/Adobe Acrobat
Rina Chokshi, 2001. MEMBER OF PhD COMMITTEE FOR. Sherrie Singleton (98 -99'). Eileen Brantley (99'). Crystal Saunders (00'). Karmardi Mills (98').
www.uri.edu/facsen/CV_N_Zawia.pdf
Chokshi, Rina J., Hossein Zia, Harpreet K. Sandhu, Navnit H. Shah and Waseem A. Malick. "Improving the Dissolution Ration of Poorly Water Soluble Drug by ...
www.uri.edu/library/faculty_publications/2007/bps07.html
Chokshi, Rina (Docs: 1). Choma, Joshua R (Docs: 1). Chong, Wong (Docs: 1). Chopy, Katelyn (Docs: 2). Chou, Dienfang (Docs: 1). Choudhury, Arpita (Docs: 1).
digitalcommons.uri.edu/authors.html
Shaw, Reena L (2005) Enforcement and compliance in the Northeast groundfish ... Chokshi,Rina (2004) Evaluation of hot -melt extrusion technology to improve ...
digitalcommons.uri.edu/dissertations/
Chockshi, Rina J., Navnit A. Shah, Harpreet K. Sandhu, Ahmad W. Malick ... Dong, Zedong, Ashish Chatterji, Harpreet Sandhu, Duk Soon Choi, HiteshChokshi ...
www.uri.edu/library/faculty_publications/2008/bps.08.html










University of Rhode Island , usa




  1. The University of Rhode Island is the principal public research as well as the land grant and sea grant university for the state of Rhode Island. Its main campus is located in the village of Kingston in southern Rhode Island. Wikipedia
  2. Address: 45 Upper College Rd, Kingston, RI 02881, United States








Map of university of rhode island












University of Rhode Island. Bay Campus. North Kingstown, Rhode Island.

Wednesday, 13 May 2015

Susan Heavey


Susan Heavey

Susan Heavey

Postdoctoral Researcher at Trinity College Dublin
Ireland
https://ie.linkedin.com/pub/susan-heavey/40/624/7a9

Summary

She is a postdoctoral researcher in the Department of Surgery at Trinity College Dublin. My key interests are: targeted therapies, signalling pathways in cancer, biomarker identification & validation, resistance to cancer therapies, personalized medicine and translational research.

Education


Trinity College, Dublin

Postgraduate Diploma, Statistics

In depth modules covering statistical analysis, regression and design & analysis of experiments

Trinity College, Dublin

BA (Mod), Molecular Medicine

Thesis entitled: Investigating Mechanisms of Resistance to Cancer Therapies
Major modules included molecular oncology, immunology, biochemistry, molecular biology, medicinal chemistry and statistics.
(Open)2 honors and awards


Loreto Abbey Dalkey

Experience



Postdoctoral Researcher

Trinity College Dublin
– Present (5 months)Department of Surgery
Project title: Understanding the role of cancer stem-like cells in resistance to radiation using a clinically-relevant model of radioresistance in oesophageal adenocarcinoma.


Postdoctoral Researcher

Trinity College Dublin
– (1 month)Department of Clinical Medicine
Project title: Targeting a novel kinase in lung cancer.

Funding: Enterprise Ireland & Inflection Bioscience (one month feasibility study).

Techniques: FACS, apoptosis & proliferation assays, phosphoprotein profiling.


PhD candidate

Trinity College Dublin
– (3 years)Institute of Molecular Medicine, Trinity Centre, St. James Hospital
Project Title: Identification of biomarkers of response & resistance to PI3K targeted inhibition in NSCLC.

Funding: Irish Cancer Society Scholarship (Grant code CRS11HEA).

Research Areas: PI3K & related pathway mutation status in NSCLC patient samples, targeted and co-targeted inhibition of the PI3K pathway in NSCLC, strategies for inhibiting the PI3K-NFκB axis in cisplatin resistant NSCLC, development and characterisation of a panel of PI3K-mTOR dual inhibitor resistant NSCLC cell lines.

Techniques: Cell culture, SDS-PAGE, Western blot, RTPCR, QPCR, gene expression arrays, phosphoprotein expression arrays, BrdU proliferation assays, ELISA, High Content Analysis (HCA), Multiparameter apoptosis assays, DNA sequencing, miRNA expression profiling, clonogenic assays, irradiation, immunofluorescence, drug combination studies, FACS, hypoxia studies, densitometry, statistical analysis.


Intern - Thoracic Oncology

Trinity College Dublin
– (4 months)Institute of Molecular Medicine, Trinity Centre, St. James Hospital
Internship in the Thoracic Oncology Research Group, conducting further investigation into data generated during my final year research project.

Research area: Cisplatin Resistance in Non Small Cell Lung Cancer

Techniques: Cell Culture, RTPCR, Western Blot, High Content Analysis,


Intern - Immunology

Case Western Reserve University
– (3 months)Centre for Global Health and Disease, CWRU
Internship in the Hise laboratory at the Centre for Global Health & Disease.

Research area: The immune response to Rift Valley Fever Virus.

Techniques: Cell culture, Transfections, Molecular Cloning, DNA Isolation, ELISA, Dissections and Lymphocyte Isolation.

Publications



Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC.(Link)

Cancer Biology & Therapy
July 15, 2014
Chemoresistance is a major therapeutic challenge to overcome in NSCLC, in order to improve the current survival rates of<15% at 5 years. We and others have shown increased PI3K signaling in NSCLC to be associated with a more aggressive disease, and a poorer prognosis. In this study, targeted inhibition of three strategic points of the PI3K-NFκB axis was performed with the aim of exploiting...more-


Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC.(Link)

Cancer Treatment Review
August 26, 2013
The PI3K/AKT/mTOR pathway regulates cell growth and proliferation and is often dysregulated in cancer due to mutation, amplification, deletion, methylation and post-translational modifications. We and others have shown that activation of this pathway in non-small cell lung cancer (NSCLC) leads to a more aggressive disease which correlates to poor prognosis for patients. A multitude of selective...more
3 authors
  • Susan Heavey


Chapter 7: Targeted Therapies in Non-Small Cell Lung Cancer(Link)

Lung Cancer: A Comprehensive Overview (Kathy Gately, Nova Publishers)


Targeting nuclear factor-kappa B to overcome resistance to chemotherapy.(Link)

Front Oncol.
2013
Godwin P, Baird AM, Heavey S, Barr MP, O’Byrne KJ, Gately K. Targeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy. Front. Oncol. doi: 10.3389/fonc.2013.00120.

Honors & Awards

Poster Prize (Translational Medicine category)

9th International Cancer Conference

Title of Poster: In depth molecular characterisation of a novel panel of PI3K-mTOR inhibitor resistant NSCLC cell lines.

Scholar-in-training Award

American Association for Cancer Research

Scholar-in-Training Award supported by Aflac, Inc. to support my attendance at the AACR Special Conference on Targeting the PI3K-mTOR Network in Cancer, being held from September 14–17, 2014 in Philadelphia, PA, USA.

Travel Award

European Society for Medical Oncology

ESMO Travel Award to attend the ESMO Symposium on Signalling Pathways in Cancer 2014:Targeting the PI3K/AKT/mTOR pathway.

Finalist: Cell Imaging Competition

GE Healthcare

Finalist in the 2013 cell imaging competition, with my image being shown in Times Square, NYC. https://www.youtube.com/watch?v=4LlpabzT7Wk

Poster Prize (Basic Science Category)

British Thoracic Oncology Group Annual Conference

Title of Poster: NFκB-IκBα Interaction: a Mechanism of Resistance to Cisplatin in NSCLC.

Cancer Research Ireland Scholarship

Irish Cancer Society Research

Title of grant: The Identification of Biomarkers that Predict Sensitivity/Resistance to PI3K Inhibitors.

Highly Commended (Medical Science Category)

Undergraduate Awards of Ireland and Northern Ireland

Title of Paper: IκBα - a Mechanism of Resistance to Cisplatin in NSCLC

Margaret Ciotti Medal

TCD School of Biochemistry and Immunology

Award for highest marked undergraduate thesis in the School of Biochemistry. Title of Thesis: Investigating Mechanisms of Resistance to Cancer Therapies

Volunteer Experience & Causes



Volunteer Retail Assistant

Irish Cancer Society
– (9 months)Health


Fundraiser

Irish Cancer Society
Health
Electric Run 2014
Colour Dash 2013 & 2014
Mini Marathon 2012
Daffodil Day 2012
Cake Sales & Easter egg raffles (Loreto Abbey Dalkey), 2001-2007

Causes Susan cares about:

  • Education
  • Health
  • Science and Technology

Organizations Susan supports:

Recieved PHD May 2015













4943DFB1-21AE-49DA-8712-239BC92678AA.jpg.

 DUBLIN , IRELAND




 Map of dublin ireland

 




/////////